AVEO Pharmaceuticals Inc. (AVEO)

Oncology Corporate Profile

Stock Performance

3.5100
0.1700

HQ Location

75 Sidney Street, 4th Floor
Cambridge, MA 2139

Company Description

AVEO Pharmaceuticals is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patients' lives. AVEO's proprietary Human Response Platform provides the company unique insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics.

Website: http://www.aveopharma.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
tivozanibVEGF receptor inhibitorRenal cell carcinoma (RCC)III
tivozanib (+ nivolumab)VEGF receptor inhibitorRenal cell carcinoma (RCC)IIBristol-Myers Squibb
ficlatuzumab / AV-299HGF/c-Met pathway inhibitorAcute Myelogenous Leukemia (AML)IBiodesix
ficlatuzumab / AV-299HGF/c-Met pathway inhibitorSquamous cell carcinoma of the Head & NeckIBiodesix
AV-203anti-ErbB3 monoclonal antibodyBreast cancerPreclinical
AV-380anti-GDF15 antibodyCancer cachexiaPreclinicalNovartis
AV-203anti-ErbB3 monoclonal antibodyHead & Neck CancerPreclinical
AV-203anti-ErbB3 monoclonal antibodyOvarian cancerPreclinical
AV-203anti-ErbB3 monoclonal antibodyPancreatic cancerPreclinical

View additional information on product candidates here »

Source: http://www.aveopharma.com

Recent News Headlines

Aveo Halts Study Of Lung Cancer Drug

9/14/2016 04:19 pm

(BioPharma Dive) Sept 12, 2016 - Aveo Oncology said it would end Phase 2 trials of its lung cancer drug and second most advanced clinical candidate ficlatuzumab, revealing the shift Monday in a regulatory filing.

AVEO Initiates the Evaluation of Tivozanib in Combination with Bristol-Myers Squibb’s Opdivo® (nivolumab) in Advanced Renal Cell Carcinoma

8/15/2016 04:18 pm

(MarketWatch) Aug 15, 2016 - AVEO Oncology today announced the initiation of a clinical evaluation of AVEO’s oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), tivozanib, in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo® (nivolumab), in advanced renal cell carcinoma (RCC).

AVEO Announces Dosing of First Patient in the Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma

5/26/2016 04:37 pm

(Stockhouse) May 26,2016 - AVEO Oncology today announced that the first patient has been dosed in the Company's pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).

Valeant Outlines Heart Drug Discounts After Heavy Scrutiny

5/16/2016 12:01 pm

(NASDAQ/Dow Jones Business News) May 16, 2016 - Valeant Pharmaceuticals International Inc. said Monday that it would expand discounts for a pair of its heart drugs following heavy scrutiny over its pricing tactics.

Opinion: Medicare "Test" Would Accelerate Cancer Clinic Closings

4/21/2016 10:05 am

(The Suncoast News [Tampa, FL]) Apr 20, 2016 - For cancer patients, it's getting harder to find access to quality, affordable care. More than 300 of the nation's cancer clinics have closed since 2008, and roughly 400 are struggling to make ends meet, according to the Community Oncology Alliance.

AVEO and CANbridge Life Sciences Announce Exclusive Licensing Agreement for AV-203 Outside of North America

3/21/2016 04:54 pm

(TheStreet) Mar 21, 2016 - CANbridge plans to develop AV-203 first in esophageal squamous cell cancer (ESCC), the most prevalent form of esophageal cancer.

Aveo’s Kidney Cancer Drug Submitted For Approval In Europe

3/1/2016 05:43 pm

(Boston Business Journal/BioFlash blog) Mar 1, 2016 - An application for approval in the world’s second-largest drug market has been submitted for a kidney cancer drug developed in Cambridge by Aveo Oncology — marking a potential second act for a drug that was rejected by U.S. regulators almost three years ago.

Cancer Kills 7,500 Daily in China

1/27/2016 11:05 am

(Yahoo! News/AFP) Jan 27, 2016 - Chronic infections, smoking and pollution have contributed to skyrocketing cases of cancer in China, with an estimated 4.3 million new diagnoses last year and 2.8 million deaths, researchers said Tuesday.

AVEO and EUSA Pharma Announce Exclusive Licensing Agreement for Tivozanib in Europe

12/21/2015 06:00 pm

(Yahoo! Finance) Dec 19, 2015 - EUSA to submit marketing authorization application for tivozanib in advanced RCC in Q1 2016.

AVEO Announces Exclusive Worldwide License Agreement for the Development and Commercialization of AV-380 and Related Antibodies

8/17/2015 05:39 pm

(StreetInsider) Aug 17, 2015 - AVEO Oncology today announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO's first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), AV-380, and related antibodies, including modified or derivative forms of any such antibody.

AVEO Oncology Announces Additional Biomarker Analyses From BATON -CRC Tivozanib Study to Be Presented at the ESMO 17th World Congress on Gastrointestinal Cancer

6/30/2015 05:06 pm

(MarketWatch) June 30, 2015 - AVEO Oncology today announced that additional biomarker analyses from the BATON- (Biomarker Assessment of Tivozanib in ONcology) CRC study will be presented at the ESMO 17th World Congress on Gastrointestinal Cancer, taking place July 1-4 in Barcelona, Spain.

AVEO Announces FDA Update for Tivozanib in Colorectal Cancer

6/12/2015 04:29 pm

(NASDAQ) June 11, 2015 - AVEO Oncology today announced that it has received written feedback from the U.S. Food and Drug Administration regarding a potential pivotal study for tivozanib in the treatment of NRP-1 low colorectal cancer (CRC).

Aveo Set to Soar Today on News of Potential Drug Approval in Europe

6/4/2015 05:08 pm

(Boston Business Journal/BioFlash blog) June 4, 2015 - Shares in a biotech that was until recently written off as all but dead by most investors, Cambridge-based Aveo Oncology, are likely to soar today based on the news that European regulators will accept an application for approval of its kidney cancer drug which was rejected here in the U.S. two years ago.

Aveo Stock Doubles on News That the FDA May Reconsider Approval of Cancer Drug

5/22/2015 04:16 pm

(Boston Business Journal/Bioflash blog) May 21, 2015 - Shares of Aveo Oncology shot up today to the highest they’ve been since the high-profile rejection of its kidney cancer drug on the news that the Food and Drug Administration may now be open to reconsidering approval.

AVEO Oncology Announces Presentation of Final Results of Extension Study 902 and FDA Regulatory Feedback for Advancing Tivozanib in Renal Cell Carcinoma

5/20/2015 04:45 pm

(Yahoo! Finance) May 20, 2015 - AVEO Oncology announced today that final results from the TIVO-1 extension study, known as Study 902, in which patients with advanced renal cell carcinoma (RCC) received tivozanib as second-line treatment subsequent to disease progression on sorafenib in the Company’s Phase 3 TIVO-1 first-line RCC study, will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.

‘Safety Switch’ Kills Haywire Immune Cells in Transplant Test

5/15/2015 12:01 pm

(Bloomberg) May 14, 2015 - A “safety switch” drug by Bellicum Pharmaceuticals Inc. killed off overactive immune system cells in a study of transplant patients, raising hopes that the treatment can also be used to manage risks in an experimental class of cancer therapies.

Aveo Stock Surges Premarket on Promising Results From Colon Cancer Trial

3/6/2015 05:07 pm

(Boston Business Journal/BioFlash blog) Mar 6, 2015 - Shares of Aveo Oncology shot up in premarket trading this morning after it reported that its drug, tivozanib, appears to have stopped the growth of advanced colon cancer better than Avastin in certain patients.

AVEO Oncology Announces Presentation of Phase 2 Study Analysis Showing Longer PFS With Tivozanib Compared to Bevacizumab in Low Serum NRP-1 Patients With Advanced CRC

3/6/2015 05:04 pm

(MarketWatch) Mar 6, 2015 - AVEO Oncology today announced the presentation of final results, including a predefined biomarker analysis, from the BATON- (Biomarker Assessment of Tivozanib in ONcology) CRC study, a randomized Phase 2 clinical trial of modified FOLFOX6 combined with tivozanib or bevacizumab in metastatic colorectal cancer (CRC).

Aveo Replaces CEO Ha-Ngoc, Lays Off Most of Remaining Employees

1/8/2015 06:35 pm

(Boston Business Journal/BioFlash blog) Jan 7, 2015 - The management of the Cambridge cancer drug developer has long been criticized for the 2013 failure of its lead drug to get FDA approval.

AVEO Oncology Announces Results from Phase 2 Clinical Studies of Tivozanib in Patients with Advanced Colorectal and Kidney Cancers Presented at ESMO 2014 Congress

9/30/2014 05:58 pm

(AVEO) Sept 29, 2014 - AVEO Oncology today announced poster presentations for two Phase 2 clinical studies of tivozanib, one in metastatic colorectal cancer (mCRC) and one in renal cell carcinoma (RCC), at ESMO 2014.

CNIO Successfully Completes Its First Clinical Trial on HER-2-Negative Breast Cancer with Nintedanib

9/10/2014 06:05 am

(CNIO [Madrid, Spain]) Sept 9, 2014 - The experimental drug nintedanib, combined with standard chemotherapy with paclitaxel, causes a total remission of tumours in 50% of patients suffering from early HER-2-negative breast cancer, the most common type of breast cancer.

Basilea Gets FDA Request for More Data on Pneumonia Drug

6/25/2014 06:03 am

(Bloomberg) June 25, 2014 - Basilea Pharmaceutica AG, a Swiss developer of an antibiotic to treat pneumonia, said the U.S. Food and Drug Administration asked for more data before approving the drug. The stock fell as much as 12 percent.

Sunshine… Or Clouds? Drug Makers Grapple With Transparency Law

6/6/2014 07:00 am

(Wall Street Journal/Pharmalot blog) June 5, 2014 - For the past year, the pharmaceutical industry has been bracing for the Sunshine Act, a provision of health care reform that requires drug makers to gather and report payments and gifts to physicians.

Novartis Submits Panobinostat for FDA Approval as New Treatment for Multiple Myeloma, Gains Priority Review

6/2/2014 02:00 pm

(The Myeloma Beacon) June 2, 2014 - Panobinostat could be the next potential myeloma therapy approved by the U.S. Food and Drug Administration (FDA).

AVEO Oncology Announces Presentation of AV-203 Phase 1 Results at 2014 American Society of Clinical Oncology Annual Meeting

5/31/2014 10:45 pm

(AVEO Oncology) May 31, 2014 - AVEO Oncology today announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO’s ErbB3 (HER3) inhibitory antibody candidate. Among the results, the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned dose of AV-203 monotherapy.

AVEO Oncology Announces Presentation of AV-203 Phase 1 Results at 2014 American Society of Clinical Oncology Annual Meeting

5/31/2014 12:04 pm

(AVEO Oncology) May 31, 2014 - AVEO Oncology today announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO’s ErbB3 (HER3) inhibitory antibody candidate. Among the results, the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned dose of AV-203 monotherapy.

Aveo to Co-Develop NSCLC Candidate with Biodesix' VeriStrat

4/10/2014 04:52 pm

(Genetic Engineering News) Apr 10, 2014 - Aveo Oncology and Biodesix said today they will co-develop Aveo’s ficlatuzumab with a Biodesix companion diagnostic already on the market, VeriStrat, to identify patients with advanced non-small cell lung cancer (NSCLC) who would be most likely to benefit from the hepatocyte growth factor (HGF) inhibitory antibody.

Aveo to Co-Develop NSCLC Candidate with Biodesix' VeriStrat

4/10/2014 11:05 am

(Genetic Engineering News) Apr 10, 2014 - Aveo Oncology and Biodesix said today they will co-develop Aveo’s ficlatuzumab with a Biodesix companion diagnostic already on the market, VeriStrat, to identify patients with advanced non-small cell lung cancer (NSCLC) who would be most likely to benefit from the hepatocyte growth factor (HGF) inhibitory antibody.

AVEO Regains Worldwide Rights to AV-203

3/21/2014 05:07 pm

(MarketWatch) Mar 20, 2014 - Agreement with Biogen Idec allows AVEO to seek partner to accelerate clinical development.

Aveo, Astellas End Pact to Develop Cancer Drug Tivozanib

2/14/2014 04:16 pm

(Reuters) Feb 14, 2014 - Aveo Oncology and Astellas Pharma Inc said they would end an agreement to develop Aveo's lead experimental drug that has seen a string of failures in multiple cancer indications.

Aveo, Astellas End Pact to Develop Cancer Drug Tivozanib

2/14/2014 10:01 am

(Reuters) Feb 14, 2014 - Aveo Oncology and Astellas Pharma Inc said they would end an agreement to develop Aveo's lead experimental drug that has seen a string of failures in multiple cancer indications.

Aveo Oncology to End Breast Cancer Study Due to Low Enrollment

1/30/2014 05:17 pm

(Reuters) Jan 30, 2014 - Aveo Oncology said it would end a mid-stage trial testing its lead drug as a treatment for breast cancer, as the company did not have enough patients enrolled in the study.

AVEO and Astellas Discontinue Phase 2 Trial of Tivozanib in Breast Cancer

1/30/2014 12:43 pm

(MarketWatch) Jan 30, 2014 - AVEO Oncology today announced that AVEO and Astellas Pharma Inc. have jointly decided to discontinue the BATON (Biomarker Assessment of Tivozanib in ONcology) breast cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment.

Aveo Oncology to End Breast Cancer Study Due to Low Enrollment

1/30/2014 11:01 am

(Reuters) Jan 30, 2014 - Aveo Oncology said it would end a mid-stage trial testing its lead drug as a treatment for breast cancer, as the company did not have enough patients enrolled in the study.

AVEO and Astellas Discontinue Phase 2 Trial of Tivozanib in Breast Cancer

1/30/2014 06:04 am

(MarketWatch) Jan 30, 2014 - AVEO Oncology today announced that AVEO and Astellas Pharma Inc. have jointly decided to discontinue the BATON (Biomarker Assessment of Tivozanib in ONcology) breast cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment.

CMS to Release Physician Payment Data

1/15/2014 11:03 am

(HealthLeaders Media) Jan 15, 2014 - The federal government has issued a new policy for public disclosure of physicians' Medicare payments.

Medicare to Release Doc Pay Data This Spring

1/15/2014 06:04 am

(MedPage Today) Jan 14, 2014 - Medicare will begin releasing payment data for individual physicians on a "case-by-case basis" as soon as this spring, the Centers for Medicare and Medicaid Services (CMS) announced Tuesday.

Aveo Says Lead Drug Unlikely to Succeed in Colon Cancer Study

12/13/2013 09:13 pm

(Reuters) Dec 13, 2013 - Aveo Oncology said its lead experimental drug was unlikely to succeed in a mid-stage colon cancer study that was testing if the drug was superior to an approved treatment.

Aveo Says Lead Drug Unlikely to Succeed in Colon Cancer Study

12/13/2013 03:01 pm

(Reuters) Dec 13, 2013 - Aveo Oncology said its lead experimental drug was unlikely to succeed in a mid-stage colon cancer study that was testing if the drug was superior to an approved treatment.

AVEO Provides Update on Interim Analysis from Tivozanib Trial in Colorectal Cancer

12/13/2013 01:11 pm

(Yahoo! Finance) Dec 13, 2013 - AVEO Oncology today announced that data from a planned interim analysis of the Phase 2 BATON (Biomarker Assessment of Tivozanib in ONcology) study in patients with colorectal cancer (CRC) indicate that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population.

AVEO Provides Update on Interim Analysis from Tivozanib Trial in Colorectal Cancer

12/13/2013 07:01 am

(Yahoo! Finance) Dec 13, 2013 - AVEO Oncology today announced that data from a planned interim analysis of the Phase 2 BATON (Biomarker Assessment of Tivozanib in ONcology) study in patients with colorectal cancer (CRC) indicate that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population.

Aveo Reeling after FDA’s Rejection of Kidney Cancer Drug

8/26/2013 05:00 pm

(Boston Globe) Aug 26, 2013 - It took Aveo Pharmaceuticals Inc. seven years to develop a much anticipated kidney cancer drug. Federal regulators needed only about four hours to crush the company’s hopes.

New Health-Care Law's Success Rests on the Young

7/25/2013 11:02 am

(Wall Street Journal) July 25, 2013 - The success of the new health-care law rides in large measure on whether young, healthy people like Gabe Meiffren, a cook at a Korean-Hawaiian food cart, decide to give up a chunk of disposable income to pay for insurance.

AVEO Announces Complete Response Letter Received for Tivozanib New Drug Application in Renal Cell Carcinoma

6/10/2013 07:02 am

(MarketWatch) June 10, 2013 - AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) informing the company that the FDA will not approve in its present form the New Drug Application (NDA) for AVEO’s investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma (RCC).

Aveo's Future Depends on Triple-Negative Breast Cancer

6/6/2013 11:03 am

(TheStreet) June 6, 2013 - Aveo Oncology will succeed or fail depending on the potential for tivozanib to treat triple-negative breast cancer.

Aveo Chairman: Expect "Consequences" From Kidney Cancer Drug Debacle

5/30/2013 11:03 am

(The Street) May 29, 2013 - The thrashing of Aveo Oncology's kidney cancer drug by an FDA advisory panel earlier this month will lead to "very significant consequences" at the struggling company, said Chairman Henri Termeer, in an interview following Aveo's annual shareholder meeting.

Aveo Shares Plummet as FDA Advisory Panel Votes Down Cancer Drug

5/2/2013 05:01 pm

(Xconomy Boston) May 2, 2013 - A doomsday scenario played out for Aveo Oncology today. The Cambridge, MA-based company saw 13 of 14 members of an FDA advisory panel vote against its kidney cancer drug, tivozanib, saying it shouldn’t be cleared for sale in the U.S. because of questions about clinical trial design and the drug’s overall benefits to patients.

Aveo Fails to Win FDA Panel Backing for Kidney Cancer Drug

5/2/2013 12:04 pm

(BloombergBusinessweek) May 2, 2013 - Aveo Pharmaceuticals Inc. failed to win the backing of U.S. regulatory advisers for its lead product candidate, a kidney cancer drug, after the panelists questioned whether it was as effective as existing treatments.

U.S. FDA Staff Question Whether Aveo Drug Needs New Trial

4/30/2013 09:04 am

(Reuters) Apr 30, 2013 - Staff reviewers for the U.S. Food and Drug Administration have asked a panel of outside medical experts whether another clinical trial is needed before an experimental kidney cancer drug made by Aveo Pharmaceuticals Inc and Astellas Pharma Inc can be approved.

Aveo's Kidney Cancer Drug Won't Get FDA Panel OK

4/25/2013 11:04 am

(The Street) Apr 25, 2013 - Next week is crucial for Aveo Oncology. On Tuesday, the FDA will post to its web site the agency's clinical review of Aveo's experimental kidney cancer drug tivozanib.